HC Wainwright Reaffirms Neutral Rating for AnaptysBio (NASDAQ:ANAB)

AnaptysBio (NASDAQ:ANAB)‘s stock had its “neutral” rating reissued by HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $22.00 target price on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 50.27% from the stock’s current price.

ANAB has been the topic of a number of other reports. Wedbush reaffirmed an “outperform” rating and set a $40.00 price objective on shares of AnaptysBio in a report on Wednesday, February 12th. Truist Financial reduced their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Guggenheim decreased their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. Wells Fargo & Company boosted their target price on AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. decreased their price target on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.44.

AnaptysBio Price Performance

NASDAQ:ANAB opened at $14.64 on Tuesday. AnaptysBio has a one year low of $12.21 and a one year high of $41.31. The company has a market cap of $445.48 million and a PE ratio of -2.41. The firm has a 50-day moving average of $16.02 and a 200-day moving average of $24.46.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.89. The business had revenue of $43.11 million during the quarter, compared to the consensus estimate of $10.17 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. On average, equities research analysts expect that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 6,646 shares of AnaptysBio stock in a transaction dated Thursday, January 2nd. The stock was purchased at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the purchase, the director now directly owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. This trade represents a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

A number of institutional investors have recently modified their holdings of ANAB. Tower Research Capital LLC TRC lifted its position in shares of AnaptysBio by 131.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 1,531 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in AnaptysBio during the 4th quarter valued at about $40,000. AlphaQuest LLC increased its position in shares of AnaptysBio by 1,891.5% during the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 4,237 shares during the period. Virtus ETF Advisers LLC lifted its holdings in shares of AnaptysBio by 24.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock worth $63,000 after buying an additional 936 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of AnaptysBio by 1,585.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company’s stock valued at $75,000 after acquiring an additional 5,360 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.